Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Novartis Pharmaceuticals
Michael R Bishop; Michael Dickinson; Duncan Purtill; Pere Barba; Armando Santoro; Nada Hamad; Koji Kato; Anna Sureda; Richard Greil; Catherine Thieblemont; Franck Morschhauser; Martin Janz; Ian Flinn; Werner Rabitsch; Yok-Lam Kwong; Marie J Kersten; Monique C Minnema; Harald Holte; Esther H L Chan; Joaquin Martinez-Lopez; Antonia M S Müller; Richard T Maziarz; Joseph P McGuirk; Emmanuel Bachy; Steven Le Gouill; Martin Dreyling; Hideo Harigae; David Bond; Charalambos Andreadis; Peter McSweeney; Mohamed Kharfan-Dabaja; Simon Newsome; Evgeny Degtyarev; Rakesh Awasthi; Christopher Del Corral; Giovanna Andreola; Aisha Masood; Stephen J Schuster; Ulrich Jäger; Peter Borchmann; Jason R Westin